Results from the NAVIGATOR trial using tezepelumab suggest that targeting TSLP in patients with severe, uncontrolled asthma may prevent exacerbations as well as improve lung function based on improved prebronchodilator FEV1 values (169). The gene discussed is TSLP; the disease is asthma.